ストックスクリーナーアプリを入手
7.05
6.02%
0.40
前日終値:
$6.65
開ける：
$6.7
24時間の取引高:
433.17K
Relative Volume:
1.73
時価総額：
$129.09M
収益：
$137.27M
当期純損益:
$-123.57M
株価収益率:
-0.64
EPS:
-11.016
ネットキャッシュフロー:
$-102.89M
1週間 パフォーマンス:
+18.49%
1か月 パフォーマンス:
-5.24%
6か月 パフォーマンス:
+62.07%
1年 パフォーマンス:
-31.49%
1日の値動き範囲:
$6.51
$7.14
1週間の範囲:
$5.875
$7.14
52週間の値動き範囲:
$3.51
$10.47
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
名前
Karyopharm Therapeutics Inc
セクター
電話
617-658-0600
住所
85 WELLS AVENUE, NEWTON, MA
KPTI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
7.05 | 121.76M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-13 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 再開されました | H.C. Wainwright | Buy |
| 2023-01-19 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-08-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 開始されました | Morgan Stanley | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-07-23 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-05 | 繰り返されました | Robert W. Baird | Outperform |
| 2019-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 開始されました | B. Riley FBR | Buy |
| 2018-11-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-05-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-04-02 | 再開されました | Leerink Partners | Outperform |
| 2017-11-15 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2016-09-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | アップグレード | Jefferies | Hold → Buy |
| 2016-08-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-28 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving AverageHere's What Happened - MarketBeat
Can Karyopharm Unlock Xpovio's Growth In 2026 With Pivotal Myelofibrosis Data Ahead? - RTTNews
How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI) - Yahoo Finance
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock By Investing.com - Investing.com UK
Abate, Karyopharm Therapeutics CAO, sells $1.6k in stock - Investing.com
RBC Raises Price Target on Karyopharm Therapeutics to $23 From $19, Keeps Outperform Rating - marketscreener.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Spikes: Can Karyopharm Therapeutics Inc disrupt its industryDividend Hike & Verified Entry Point Signals - baoquankhu1.vn
Chart Watch: Will Karyopharm Therapeutics Inc outperform its industry peersJuly 2025 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Options Flow: Will Karyopharm Therapeutics Inc 25K0 stock rise with strong economyWeekly Risk Summary & Safe Entry Zone Tips - Bộ Nội Vụ
Layoff Watch: What margin trends mean for Karyopharm Therapeutics Inc stockWeekly Stock Analysis & Accurate Intraday Trading Signals - Bộ Nội Vụ
Analysts Are Bullish on Top Healthcare Stocks: Karyopharm Therapeutics (KPTI), Establishment Labs Holdings (ESTA) - The Globe and Mail
Karyopharm expects phase 3 trial data in myelofibrosis by March - Investing.com Canada
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Karyopharm Issues Preliminary 2025 Financial Results and Outlook - TipRanks
Karyopharm (KPTI) Anticipates Transformative 2026 with Key Trial Data - GuruFocus
Karyopharm Therapeutics reports preliminary 2025 revenue of $145 mln - TradingView — Track All Markets
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - marketscreener.com
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares - simplywall.st
Is Karyopharm Therapeutics Inc. stock attractive for passive investorsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - ulpravda.ru
Why Karyopharm Therapeutics Inc. (25K0) stock could rally stronglyQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Karyopharm (NASDAQ: KPTI) plans big share authorization increase to fund 2026 trials - Stock Titan
Is Karyopharm Therapeutics Inc. stock supported by innovation pipelineEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
How Karyopharm Therapeutics Inc. stock performs in weak economy2025 Trade Ideas & AI Forecasted Entry and Exit Points - Улправда
Will Karyopharm Therapeutics Inc. (25K0) stock rise with strong economyMarket Growth Summary & Scalable Portfolio Growth Ideas - Улправда
Why Karyopharm Therapeutics Inc. stock attracts global investorsRate Hike & High Accuracy Investment Entry Signals - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investorsPortfolio Gains Report & Fast Momentum Entry Tips - Улправда
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteTrend Reversal & Daily Chart Pattern Signals - Улправда
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - Bộ Nội Vụ
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
KPTI (Karyopharm Therapeutics Inc) has impressive results - uspostnews.com
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics Inc (KPTI) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):